News

Wu discusses his recent study spotlighting food source and quality as a more significant influence on CHD risk compared to simply cutting carbs or fat.

Upstream Bio announced positive topline results from the phase 2 VALIANT trial evaluating the efficacy and safety of verekitug in adults with severe asthma.

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.

In an interview with HCPLive, Emily Aman, MPH, and Rachel White, share that most marginalized children with uncontrolled asthma miss specialist visits despite caregiver support due to existing barriers.

Bress highlights the potential shortcomings of relying on the Apple Watch as a diagnostic tool for hypertension, discussing its potential for false negatives.

These data highlight the impact of rezpegaldesleukin therapy on adults with moderate-to-severe atopic dermatitis in the phase 2b REZOLVE-AD study.

FDA grants Priority Review for Takeda’s oveporexton, an oral orexin agonist for narcolepsy type 1, showing near-normal symptom control in phase 3.

Positive topline data from Hengrui’s phase 2 clinical trial of once-daily oral ribupatide highlight weight loss of up to 12.1% with no observed plateau at 26 weeks.

Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.

An interview conducted at Maui Derm 2026 highlights a presentation by Raj Chovatiya, MD, PhD, on managing atopic dermatitis and itch in 2026.

A retrospective study found an independent association between increased pain episodes in sickle cell disease and the cold in light of increasingly extreme weather.

In this segment of a Liver Lineup episode, experts discuss where the new US Dietary Guidelines miss the mark for alcohol recommendations.

A prospective study finds adolescents with MDD show faster response, fewer cognitive effects, and better tolerability with magnetic seizure therapy than adults.

Friedmann describes his research exploring the benefits of mobile telemedicine for HCV infection among persons who inject drugs in rural areas.

FLOW/SELECT suggest. GLP-1 receptor agonists may protect kidneys beyond glucose control

These positive results of Ameluz photodynamic therapy suggest the treatment is effective in actinic keratoses on the neck, trunk, and extremities.

Hardy discussed the disparity between treatment access and usage, highlighting the fact that most patients are within 10 mmHg of guideline recommendations.

An audio recap of the top 5 stories in healthcare news from the week of 02/01-02/07.

This Q&A interview with Philip Mease, MD, highlights his contribution to the ‘Psoriasis Update 2026’ talk given at the 2026 Maui Derm Hawaii meeting.

In an interview, investigators Emily Aman, MPH, and Rachel White highlight why marginalized children with uncontrolled asthma rarely see specialists.

Stay updated with the latest healthcare breakthroughs, including topline phase 2 data, FDA actions, and regulatory submissions, in this week’s essential news roundup.

This FDA News Month in Review provides a round-up of regulatory decisions from January 2026.

Ruff explains his prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, highlighting abelacimab’s efficacy and durability compared to rivaroxaban.

Investigators assessed the efficacy of switching to upadacitinib in those with atopic dermatitis who had an inadequate response to dupilumab.